Jacobs Levy Equity Management Inc. Purchases 219,100 Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS)

Jacobs Levy Equity Management Inc. grew its stake in shares of Pyxis Oncology, Inc. (NASDAQ:PYXS - Free Report) by 57.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 601,940 shares of the company's stock after acquiring an additional 219,100 shares during the quarter. Jacobs Levy Equity Management Inc. owned about 1.01% of Pyxis Oncology worth $939,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Barclays PLC lifted its holdings in shares of Pyxis Oncology by 275.0% during the third quarter. Barclays PLC now owns 64,089 shares of the company's stock valued at $235,000 after purchasing an additional 46,997 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Pyxis Oncology by 88.1% in the fourth quarter. American Century Companies Inc. now owns 299,937 shares of the company's stock worth $468,000 after acquiring an additional 140,498 shares during the period. Caption Management LLC purchased a new position in shares of Pyxis Oncology during the fourth quarter valued at approximately $35,000. Renaissance Technologies LLC lifted its position in Pyxis Oncology by 83.0% during the fourth quarter. Renaissance Technologies LLC now owns 293,354 shares of the company's stock valued at $458,000 after purchasing an additional 133,018 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in Pyxis Oncology by 35.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,051 shares of the company's stock worth $173,000 after purchasing an additional 29,105 shares during the last quarter. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Price Performance

Shares of PYXS traded down $0.02 during midday trading on Tuesday, hitting $1.21. The stock had a trading volume of 267,218 shares, compared to its average volume of 738,690. The stock's 50 day moving average is $1.05 and its 200 day moving average is $1.60. The firm has a market cap of $74.96 million, a PE ratio of -1.17 and a beta of 1.15. Pyxis Oncology, Inc. has a 1 year low of $0.83 and a 1 year high of $5.39.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.06). As a group, equities research analysts expect that Pyxis Oncology, Inc. will post -1.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PYXS has been the topic of several research analyst reports. Royal Bank of Canada reissued an "outperform" rating and set a $8.00 price target on shares of Pyxis Oncology in a report on Wednesday, March 19th. HC Wainwright restated a "buy" rating and issued a $5.00 price objective on shares of Pyxis Oncology in a research report on Monday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Pyxis Oncology presently has an average rating of "Moderate Buy" and a consensus price target of $9.00.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.